Fundamental Analysis of ESSA PHARMA INC(NASDAQ:EPIX) stock

Fundamental Rating

Taking everything into account, EPIX scores 3 out of 10 in our fundamental rating. EPIX was compared to 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for EPIX as it has an excellent financial health rating, but there are worries on the profitability. EPIX has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year EPIX has reported negative net income.

In the past year EPIX has reported a negative cash flow from operations.

EPIX had negative earnings in each of the past 5 years.

EPIX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With an excellent Return On Assets value of -17.86%, EPIX belongs to the best of the industry, outperforming 84.10% of the companies in the same industry.

With an excellent Return On Equity value of -18.34%, EPIX belongs to the best of the industry, outperforming 88.55% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-17.86%
ROE	-18.34%
ROIC	N/A

ROA(3y)-19.04%

ROA(5y)-21.91%

ROE(3y)-19.41%

ROE(5y)-22.78%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EPIX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EPIX has about the same amout of shares outstanding than it did 1 year ago.

Compared to 5 years ago, EPIX has more shares outstanding

EPIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

EPIX has an Altman-Z score of 45.50. This indicates that EPIX is financially healthy and has little risk of bankruptcy at the moment.

With an excellent Altman-Z score value of 45.50, EPIX belongs to the best of the industry, outperforming 96.75% of the companies in the same industry.

EPIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	45.5

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

EPIX has a Current Ratio of 40.75. This indicates that EPIX is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of EPIX (40.75) is better than 99.15% of its industry peers.

EPIX has a Quick Ratio of 40.75. This indicates that EPIX is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of EPIX (40.75) is better than 99.15% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	40.75
Quick Ratio	40.75

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.27% over the past year.

EPS 1Y (TTM)20.27%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q6.67%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

EPIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.68% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-33.96%

EPS Next 2Y-33.35%

EPS Next 3Y-17.63%

EPS Next 5Y24.68%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

EPIX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year EPIX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

EPIX's earnings are expected to decrease with -17.63% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-33.35%

EPS Next 3Y-17.63%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for EPIX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ESSA PHARMA INC

NASDAQ:EPIX (4/19/2024, 7:00:02 PM)

6.32

-0.4 (-5.95%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap279.60M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-17.86%
ROE	-18.34%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	40.75
Quick Ratio	40.75
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)20.27%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-33.96%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ESSA PHARMA INC (EPIX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens